Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : COYA 302,Abatacept
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Coya Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Coya will in-license the proposed Abatacept biosimilar for the development of Coya’s combination product for neurodegenerative diseases, COYA 302, an investigational combination biologic for subcutaneous administration, comprised o...
Product Name : COYA 302
Product Type : Protein
Upfront Cash : Undisclosed
March 20, 2023
Lead Product(s) : COYA 302,Abatacept
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Coya Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Coya Shows IL-2 Combo Benefits in Frontotemporal Dementia Open Label Study
Details : COYA 302 consists of a combination of low-dose IL-2 and CTLA4-Ig, is currently being investigated for the treatment in patients with Frontotemporal Dementia (FTD).
Product Name : COYA 302
Product Type : Protein
Upfront Cash : Inapplicable
April 24, 2025
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kashiv’s Phase 1 Abatacept Biosimilar KSHB002 Shows Success
Details : KSHB002 (abatacept) is a biosimilar of orencia, a selective T cell costimulation modulator indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
Product Name : KSHB002
Product Type : Protein
Upfront Cash : Inapplicable
January 28, 2025
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COYA 302,Abatacept
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Dr. Reddy's Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Coya granted Dr. Reddy’s an exclusive license to commercialize COYA 302, a proprietary co-pack kit containing combination of low dose interleukin-2 and CTLA-4 Ig (abatacept) for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : COYA 302
Product Type : Protein
Upfront Cash : Undisclosed
June 12, 2023
Lead Product(s) : COYA 302,Abatacept
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Dr. Reddy's Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Abatacept,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Treatment with Orencia (abatacept) versus placebo displayed a strong but not statistically significant improvement in the primary endpoint of time to recovery as measured by day of hospital discharge.
Product Name : Orencia
Product Type : Protein
Upfront Cash : Inapplicable
February 06, 2022
Lead Product(s) : Abatacept,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abatacept,Methotrexate,Undisclosed
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. Food and Drug Administration Approves Orencia® (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD) in Patients Undergoing Hematopoietic Stem Cell Transplant Donor.
Product Name : Orencia
Product Type : Protein
Upfront Cash : Inapplicable
December 15, 2021
Lead Product(s) : Abatacept,Methotrexate,Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ABA2 trial assessed the impact of Orencia on the prevention of severe aGvHD, when added to a standard GvHD prophylactic regimen administered to patients with hematologic malignancies receiving a stem cell transplant from an unrelated, HLA-matched or ...
Product Name : Orencia
Product Type : Protein
Upfront Cash : Inapplicable
August 24, 2021
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ABA2 trial assessed the impact of Orencia on the prevention of severe aGvHD, when added to a standard GvHD prophylactic regimen administered to patients with hematologic malignancies receiving a stem cell transplant from an unrelated, HLA-matched or ...
Product Name : Orencia
Product Type : Protein
Upfront Cash : Inapplicable
August 23, 2021
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orencia is an immunomodulator that disrupts the continuous cycle of T-cell activation, psoriatic arthritis and juvenile idiopathic arthritis. Orencia targets unique and fundamental drivers of disease, resulting in improved efficacy and durability in sero...
Product Name : Orencia
Product Type : Protein
Upfront Cash : Inapplicable
March 11, 2021
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Infliximab,Abatacept,Cenicriviroc
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NIH Begins Large Clinical Trial to Test Immune Modulators for Treatment of COVID-19
Details : The three drugs are Janssen’s infliximab (Remicade), Bristol Myers Squibb’s (BMS) abatacept (Orencia) and AbbVie’s investigational late-stage drug Cenicriviroc (CVC).
Product Name : Remicade
Product Type : Antibody
Upfront Cash : Inapplicable
October 16, 2020
Lead Product(s) : Infliximab,Abatacept,Cenicriviroc
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable